Cost and mortality prediction using polymerase chain reaction pathogen detection in sepsis: Evidence from three observational trials

Critical Care

Volumn 14, Issue 5, 2010, Pages

  Lehmann, Lutz E ^a   Herpichboehm, Bernd ^b   Kost, Gerald J ^c   Kollef, Marin H ^d   Stüber, Frank ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b ROCHE DIAGNOSTICS GMBH   (Germany)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMICROBIAL THERAPY; ARTICLE; BLOOD CULTURE; COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; MONTE CARLO METHOD; MORTALITY; MULTIPLEX POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; SEPSIS; CLINICAL TRIAL; COMPARATIVE STUDY; COST; ECONOMICS; HUMAN; MICROBIOLOGY; MULTICENTER STUDY; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; PROSPECTIVE STUDY; THEORETICAL MODEL; TREATMENT OUTCOME;

COSTS AND COST ANALYSIS; HEALTH CARE COSTS; HUMANS; MODELS, THEORETICAL; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; SEPSIS; TREATMENT OUTCOME;

EID: 77957897126     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc9294     Document Type: Article

References (36)

1. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003, 348:1546-1554. 10.1056/NEJMoa022139, 12700374.
2. Byl B, Clevenbergh P, Jacobs F, Struelens MJ, Zech F, Kentos A, Thys JP. Impact of infectious diseases specialists and microbiological data on the appropriateness of antimicrobial therapy for bacteremia. Clin Infect Dis 1999, 29:60-66. discussion 67-68, 10.1086/520182, 10433566.
3. Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kollef MH. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000, 118:146-155. 10.1378/chest.118.1.146, 10893372.
4. Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999, 115:462-474. 10.1378/chest.115.2.462, 10027448.
5. Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, Suppes R, Feinstein D, Zanotti S, Taiberg L, Gurka D, Kumar A, Cheang M. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006, 34:1589-1596. 10.1097/01.CCM.0000217961.75225.E9, 16625125.
6. Kumar A, Ellis P, Arabi Y, Roberts D, Light B, Parrillo JE, Dodek P, Wood G, Simon D, Peters C, Ahsan M, Chateau D, . Cooperative Antimicrobial Therapy of Septic Shock Database Research Group Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. Chest 2009, 136:1237-1248. 10.1378/chest.09-0087, 19696123, Cooperative Antimicrobial Therapy of Septic Shock Database Research Group.
7. Lehmann LE, Hunfeld KP, Steinbrucker M, Brade V, Book M, Seifert H, Bingold T, Hoeft A, Wissing H, Stuber F. Improved detection of blood stream pathogens by real-time PCR in severe sepsis. Intensive Care Med 2009, 36:49-56. 10.1007/s00134-009-1608-z, 19756512.
8. Bouza E, Sousa D, Munoz P, Rodriguez-Creixems M, Fron C, Lechuz JG. Bloodstream infections: a trial of the impact of different methods of reporting positive blood culture results. Clin Infect Dis 2004, 39:1161-1169. 10.1086/424520, 15486840.
9. Hugonnet S, Sax H, Eggimann P, Chevrolet JC, Pittet D. Nosocomial bloodstream infection and clinical sepsis. Emerg Infect Dis 2004, 10:76-81.
10. Vincent JL, Sakr Y, Sprung CL, Ranieri VM, Reinhart K, Gerlach H, Moreno R, Carlet J, Le Gall JR, Payen D. Sepsis in European intensive care units: results of the SOAP study. Crit Care Med 2006, 34:344-353. 10.1097/01.CCM.0000194725.48928.3A, 16424713.
11. Kost GJ, Tang Z, Tran NK, Curd EE, Louie RF, Albertson TE, Derlet RW, Azari R. Economic Implications of Optimal Diagnosis and Treatment of Sepsis, Work in Progress: Marginal Penalties, Antibiotic Alterations, and Outcome Hypotheses. Scandinavian Journal of Clinical and Laboratory Investigation 2003, 63:16-26.
12. Bloos F, Hinder F, Becker K, Sachse S, Dessap AM, Straube E, Cattoir V, Brun-Buisson C, Reinhart K, Peters G, Bauer M. A multicenter trial to compare blood culture with polymerase chain reaction in severe human sepsis. Intensive Care Med 2010, 36:241-247. 10.1007/s00134-009-1705-z, 19924398.
13. Chan KY, Lam HS, Cheung HM, Chan AK, Li K, Fok TF, Ng PC. Rapid identification and differentiation of Gram-negative and Gram-positive bacterial bloodstream infections by quantitative polymerase chain reaction in preterm infants. Crit Care Med 2009, 37:2441-2447. 10.1097/CCM.0b013e3181a554de, 19531943.
14. Florent M, Katsahian S, Vekhoff A, Levy V, Rio B, Marie JP, Bouvet A, Cornet M. Prospective evaluation of a polymerase chain reaction-ELISA targeted to Aspergillus fumigatus and Aspergillus flavus for the early diagnosis of invasive aspergillosis in patients with hematological malignancies. J Infect Dis 2006, 193:741-747. 10.1086/500466, 16453271.
15. Jordan JA, Durso MB. Real-time polymerase chain reaction for detecting bacterial DNA directly from blood of neonates being evaluated for sepsis. J Mol Diagn 2005, 7:575-581. 1867550, 16258155.
16. Struelens MJ. Detection of microbial DNAemia: does it matter for sepsis management?. Intensive Care Med 2010, 36:193-195. 10.1007/s00134-009-1710-2, 19924397.
17. Lehmann LE, Alvarez J, Hunfeld KP, Goglio A, Kost GJ, Louie RF, Raglio A, Regueiro BJ, Wissing H, Stuber F. Potential clinical utility of polymerase chain reaction in microbiological testing for sepsis. Crit Care Med 2009, 37:3085-3090. 10.1097/CCM.0b013e3181b033d7, 19633541.
18. Garnacho-Montero J, Ortiz-Leyba C, Herrera-Melero I, Aldabo-Pallas T, Cayuela-Dominguez A, Marquez-Vacaro JA, Carbajal-Guerrero J, Garcia-Garmendia JL. Mortality and morbidity attributable to inadequate empirical antimicrobial therapy in patients admitted to the ICU with sepsis: a matched cohort study. J Antimicrob Chemother 2008, 61:436-441. 10.1093/jac/dkm460, 18056733.
19. Hyle EP, Lipworth AD, Zaoutis TE, Nachamkin I, Bilker WB, Lautenbach E. Impact of inadequate initial antimicrobial therapy on mortality in infections due to extended-spectrum beta-lactamase-producing enterobacteriaceae: variability by site of infection. Arch Intern Med 2005, 165:1375-1380. 10.1001/archinte.165.12.1375, 15983286.
20. Kang CI, Kim SH, Park WB, Lee KD, Kim HB, Kim EC, Oh MD, Choe KW. Bloodstream infections caused by antibiotic-resistant gram-negative bacilli: risk factors for mortality and impact of inappropriate initial antimicrobial therapy on outcome. Antimicrob Agents Chemother 2005, 49:760-766. 10.1128/AAC.49.2.760-766.2005, 547233, 15673761.
21. MacArthur RD, Miller M, Albertson T, Panacek E, Johnson D, Teoh L, Barchuk W. Adequacy of early empiric antibiotic treatment and survival in severe sepsis: experience from the MONARCS trial. Clin Infect Dis 2004, 38:284-288. 10.1086/379825, 14699463.
22. Metan G, Uzun O. Impact of initial antimicrobial therapy in patients with bloodstream infections caused by Stenotrophomonas maltophilia. Antimicrob Agents Chemother 2005, 49:3980-3981. 10.1128/AAC.49.9.3980-3981.2005, 1195400, 16127088.
23. Lehmann LE, Hunfeld KP, Emrich T, Haberhausen G, Wissing H, Hoeft A, Stuber F. A multiplex real-time PCR assay for rapid detection and differentiation of 25 bacterial and fungal pathogens from whole blood samples. Med Microbiol Immunol 2008, 197:313-324. 10.1007/s00430-007-0063-0, 18008085.
24. MacCallum DM, Odds FC. Need for early antifungal treatment confirmed in experimental disseminated Candida albicans infection. Antimicrob Agents Chemother 2004, 48:4911-4914. 10.1128/AAC.48.12.4911-4914.2004, 529222, 15561880.
25. Clec'h C, Timsit JF, De Lassence A, Azoulay E, Alberti C, Garrouste-Orgeas M, Mourvilier B, Troche G, Tafflet M, Tuil O, Cohen Y. Efficacy of adequate early antibiotic therapy in ventilator-associated pneumonia: influence of disease severity. Intensive Care Med 2004, 30:1327-1333. 10.1007/s00134-004-2292-7, 15197443.
26. Angus DC, Linde-Zwirble WT, Clermont G, Ball DE, Basson BR, Ely EW, Laterre PF, Vincent JL, Bernard G, van Hout B. Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis. Crit Care Med 2003, 31:1-11. 10.1097/00003246-200301000-00001, 12544986.
27. Pop-Vicas AE, D'Agata EM. The rising influx of multidrug-resistant gram-negative bacilli into a tertiary care hospital. Clin Infect Dis 2005, 40:1792-1798. 10.1086/430314, 15909268.
28. Falagas ME, Tassios PT. Enhanced and earlier detection of bacteremia and fungemia by multiplex polymerase chain reaction: how much enhanced, how much earlier, and at what cost?. Crit Care Med 2008, 36:1660-1661. 10.1097/CCM.0b013e31817045e5, 18448928.
29. McLaughlin AM, Hardt J, Canavan JB, Donnelly MB. Determining the economic cost of ICU treatment: a prospective "micro-costing" study. Intensive Care Med 2009, 35:2135-2140. 10.1007/s00134-009-1622-1, 19756509.
30. Chrusch CA, Olafson KP, McMillan PM, Roberts DE, Gray PR. High occupancy increases the risk of early death or readmission after transfer from intensive care. Crit Care Med 2009, 37:2753-2758. 10.1097/CCM.0b013e3181a57b0c, 19707139.
31. Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J, Gea-Banacloche J, Keh D, Marshall JC, Parker MM, Ramsay G, Zimmerman JL, Vincent JL, Levy MM, . Surviving Sepsis Campaign Management Guidelines Committee Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 2004, 32:858-873. 10.1097/01.CCM.0000117317.18092.E4, 15090974, Surviving Sepsis Campaign Management Guidelines Committee.
32. Harbarth S, Garbino J, Pugin J, Romand JA, Lew D, Pittet D. Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis. Am J Med 2003, 115:529-535. 10.1016/j.amjmed.2003.07.005, 14599631.
33. Louie RF, Tang Z, Albertson TE, Cohen S, Tran NK, Kost GJ. Multiplex polymerase chain reaction detection enhancement of bacteremia and fungemia. Crit Care Med 2008, 36:1487-1492. 10.1097/CCM.0b013e31816f487c, 18434904.
34. Karlsson S, Ruokonen E, Varpula T, Ala-Kokko TI, Pettila V. Long-term outcome and quality-adjusted life years after severe sepsis. Crit Care Med 2009, 37:1268-1274. 10.1097/CCM.0b013e31819c13ac, 19242321.
35. Fowler RA, Hill-Popper M, Stasinos J, Petrou C, Sanders GD, Garber AM. Cost-effectiveness of recombinant human activated protein C and the influence of severity of illness in the treatment of patients with severe sepsis. J Crit Care 2003, 18:181-191. discussion 191-184, 10.1016/j.jcrc.2003.08.009, 14595571.
36. Manns BJ, Lee H, Doig CJ, Johnson D, Donaldson C. An economic evaluation of activated protein C treatment for severe sepsis. N Engl J Med 2002, 347:993-1000. 10.1056/NEJMsa020969, 12324556.